AllSight
Companies · PLSE · Surgical & Medical Instruments & Apparatus

PULSE BIOSCIENCES, INC. (PLSE)

PULSE BIOSCIENCES, INC. (PLSE) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.

PULSE BIOSCIENCES, INC. (PLSE) stock — financials & valuation

Key numbers for PULSE BIOSCIENCES, INC. (PLSE): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.

AllSight quality score: 30/100 — a percentile rank of PULSE BIOSCIENCES, INC.’s fundamentals against Manufacturing peers, weakest on profitability. A quality ranking, not a price prediction.

Market cap$3.6B
P / S2999.2×
EV / EBITDA-42.1×
Gross margin0.3%
Operating margin-7007.8%
Net margin-6755.8%
Return on equity-80.5%
ROIC3917.1%
Debt / equity0.0×
Dividend yield0.0%

Is PULSE BIOSCIENCES, INC. overvalued? P/B looks overvalued vs its 5-year range.

Independent of the events above — derived from PULSE BIOSCIENCES, INC.’s own financial statements and shown as context, never as advice.

Sep 15, 2026100-patient enrollment
Pulse Biosciences doubles thyroid study enrollment, but efficacy data still lies ahead
Sep 15, 2026$85M equity facility
Pulse Biosciences replaces nearly exhausted ATM with new $85M equity facility
Aug 6, 2026
Quarterly-results cover filed; the actual financial update is missing
Aug 6, 2026
Optional $75 million ATM opens funding capacity without immediate dilution
Related companies in Surgical & Medical Instruments & Apparatus
Open live on AllSight — the whole market, decoded →

About AllSight · Editorial standards & method · Contact